Most founders spend their careers chasing the next big market. Sanjeev Saxena has spent his chasing the same small one - the clinic that can't afford a lab, the town that's a day's drive from the nearest hospital, the person who finds out too late. For more than 30 years and across at least four companies, he has kept re-engineering a single idea: move the cancer test to where the patient actually is, and make it cheap enough that geography stops deciding who lives.
His current attempt is Harae Dx Corp., a small company headquartered at 4900 Hopyard Road in Pleasanton, California, where Saxena is founder, CEO and CTO. The pitch is deceptively plain. Instead of shipping a specimen off to a distant lab and waiting days for results, Harae Dx wants to run the whole thing on site - on a proprietary "lab-on-a-disc" that uses centrifugal microfluidics to spin a sample through a test in roughly half an hour.
Figures per Harae Dx company materials.
01 / The one ideaBring the diagnosis to the patient
To understand Harae Dx, it helps to rewind to the sentence Saxena has been repeating in various forms for two decades. He wants, in his words, to make medical care available to "the 80 percent of the world who are not being served today" - through what he calls distributive yet connected point-of-care systems, at little cost, in villages, cities and slums.
That framing treats the central lab less as a convenience and more as a bottleneck. In a big city with insurance, a suspicious result becomes an appointment. In much of the world, the same result becomes a logistics problem: no nearby lab, no affordable test, no early warning. Saxena's whole body of work is an argument that this is an engineering problem, not an inevitability.
Make medical care available to the 80 percent of the world who are not being served today. Sanjeev Saxena
02 / The spinning discWhy a CD-sized lab matters
The technical heart of the work is centrifugal microfluidics - the "lab-on-a-disc." Picture a plastic disc about the size of a CD, etched with tiny channels and chambers. Spin it, and centrifugal force does the pipetting, mixing and separating that a bench full of instruments and a trained technician would normally handle. Add reagents that light up in the presence of specific cancer biomarkers, and the read-out can happen right there, without couriering a vial to a third-party lab.
The appeal is not that a disc is clever. It is that a disc is portable, self-contained and cheap to make at volume - which is exactly what you need if the goal is a device a minimally trained worker can run in a place with no lab and no pathologist. Harae Dx describes the target set of conditions as ovarian, cervical and breast cancer, the kinds of cancers where early detection changes outcomes the most.
Why send the sample to the lab when the lab fits in a box?
03 / The long run-upFour companies, one target
Harae Dx did not appear from nowhere. It is the latest node in a career-long chain. Saxena is a trained engineer with, by his own accounting, more than 30 years in the life-science and biomedical space, and he has a habit of co-founding companies that circle the same problem from different angles.
Before Harae Dx there was POC Medical Systems, which he founded in 2013 and ran as chairman and CEO. Its portable platforms - MammoAlert and Pandora CDx - were built to bring breast-cancer screening to emerging markets, the "lab in a box" idea aimed at places like Mexico City. In January 2017, POC announced a $21 million Series A to push that work forward. Earlier still he co-founded Scanis, which worked on breast-cancer detection using computer-aided detection, and Actis Biologics, an Indian biotech where he ran operations and raised over $15 million. He was also a contributor to the public offering of Sepragen, and is associated with Telesto Diagnostics.
Add it up and the numbers are substantial for a founder working this far from the venture spotlight: across his ventures Saxena has raised more than $70 million. But the through-line is not the capital. It is that each company is a slightly smaller, slightly cheaper version of the last - the same test, pushed closer to the patient each time.
Approximate, per public company materials and interviews.
04 / The label that fitsSocial entrepreneur, deep-tech founder
Saxena has been described as a social entrepreneur, and he seems comfortable with it - but the label undersells the engineering. He is not running a charity; he is trying to make the economics of early detection work in markets everyone else writes off. That combination - mission on one side, microfluidics and manufacturing cost on the other - is the actual product.
The recognition has followed the pattern. He received the Udhog Lagu award and a European Science award, and was nominated by Ernst & Young for Entrepreneur of the Year in India in 2011. He also sits on the board of the Texas Tech Research Park - a role well outside his California base, and a small sign of how far his network reaches beyond any single company.
A social entrepreneur isn't someone who talks about impact. It's someone who spends 30 years shrinking the price of a test until it fits a village budget.
05 / What's nextThe hard part is still shipping
The honest read on Harae Dx is that it is early. It is a six-person company with a big claim and a small footprint, backed by the hardware accelerator HAX (part of SOSV) and a Series A that closed in late 2022. Reported performance - around 85% sensitivity and 91% specificity - is promising on paper, but the distance between a promising disc and a deployed, regulated, trusted diagnostic is exactly where medical-device dreams usually stall.
What makes Saxena worth watching is that he has walked this road before, all the way from prototype to funded product to emerging-market deployment, and then chosen to start over smaller. That is an unusual instinct. Most founders, having raised $21 million for a portable screening company, would defend the territory. He left to build something more compact. The disc is the newest expression of a question he has refused to put down: how do you catch cancer early when the patient is nowhere near a hospital?
If Harae Dx works, the answer will spin on a piece of plastic the size of a CD, in a clinic that never had a lab. If it doesn't, the odds are good he'll build a fifth company and try again - a little smaller, a little cheaper, a little closer to the person who needs it.